BRCA2 and pancreatic adenocarcinoma: Both germline variants and somatic mutations of BRCA1/2 (β > 0.32) dominantly contributed to HRD in BRCA and OV, while only germline BRCA2 contributed to HRD in PAAD (Figure 2C).